Monopar Therapeutics (MNPR) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Oculis (OCS) over the past year, losing 15.0% versus a loss of 55.4%. Over five years, MNPR leads with a +241.3% price change compared with -13.4% for OCS. Monopar Therapeutics is the larger company by market cap ($562.3 million vs $523.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | OCS |
|---|---|---|
| Share price | $83.78 | $8.50 |
| Market cap | $562.35M | $523.50M |
| 1-day change | +5.29% | -2.52% |
| YTD return | +28.30% | -57.44% |
| 1-year return | -14.96% | -55.40% |
| 5-year return | +241.26% | -13.44% |
| EPS (TTM) | $-2.20 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $34.48 |
| 52-week low | $50.07 | $8.30 |
| Distance from 52-week high | -32.88% | -75.34% |
| Average volume | 218.50K | 263.57K |
| Shares outstanding | 6.71M | 61.59M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed OCS by 40.4 percentage points over the past year.
MNPR vs OCS FAQ
Which is bigger, Monopar Therapeutics or Oculis?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $562.35M compared with $523.50M for Oculis (OCS).
Which stock has performed better over the past year, MNPR or OCS?
MNPR returned -14.96% over the past 12 months, compared with -55.40% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.